Merck & Co. Stock - Long-term growth story and business model on Saturday review
20.06.2026 - 13:48:31 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 13:45 UTC. Details in the imprint.
Merck & Co. (US58933Y1055) remains one of the largest global pharma players by market value. Instead of a fresh company-specific headline this Saturday, the focus is on the long-term growth story, analyst expectations and the structure of the business model.
All news and background on Merck & Co. stock
Keytruda, vaccines and a solid balance sheet shape the long-term case for Merck & Co., with analysts tracking earnings trends and pipeline milestones closely.
What analyst data indicate
On recent data, Merck & Co. stock carries a consensus rating of "Moderate Buy", with an average price target around $128 per share according to MarketBeat, implying mid-single-digit percentage upside from current levels.
The same overview shows a market capitalization of roughly $281.6 billion and a dividend yield close to 3.0%, underlining the blend of income and growth that many large-cap pharma investors seek.
Long-term growth story on Saturday
Merck & Co. describes itself as a global biopharmaceutical company focused on prescription medicines, vaccines, biologic therapies and animal health products, with operations dating back to 1891.
Key long-term growth drivers are oncology and vaccines, where management has repeatedly highlighted the contribution of blockbuster cancer drug Keytruda and human papillomavirus vaccine Gardasil in its investor materials. Company IR information on products and strategy
The product behind the stock
Keytruda, Merck's immuno-oncology therapy for various cancers, has become a central pillar of the company's revenue base and is approved in numerous indications worldwide, making it one of the most closely watched drugs in global pharma.
Where the stock trades today
Merck & Co. shares (US58933Y1055) last closed on the New York Stock Exchange at $114.04 on 06/18/2026, according to recent market data.
Key facts on Merck & Co. stock
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- WKN: A0YD8Q
- Ticker: MRK
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 114.04 USD
- Market cap: 281.65 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Standard & Poor's 500 index, Dow Jones Industrial Average
- Next earnings date: 07/25/2026 (company calendar, subject to change)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
